Herndon, VA, May 28, 2020 (GLOBE NEWSWIRE) — The Center for Innovative Technology (CIT) today announced that CIT GAP Funds has made a follow-on investment in Vienna, Va.-based MetiStream, developer of a platform that uses big data, Natural Language Processing (NLP) and machine learning to reveal hidden insights in unstructured clinical data. Since CIT’s initial investment earlier this year, MetiStream has launched Ember Clinical Reviewer (CR), a solution to accelerate the analysis of patient and population data for COVID-19 and other clinically focused use cases by leveraging Ember’s advanced NLP and artificial intelligence (AI) capabilities. The additional funding from GAP Funds will be used for product enhancements, and increased marketing and sales efforts.As it pertains to the current COVID-19 pandemic, every health system in the U.S. is rapidly generating large amounts of data that can be used to more effectively identify and manage patients infected with or immune to COVID-19 infection. This data, such as symptoms or health risk factors, is buried within the free-text clinical notes and documentation of electronic health records (EHR). The unstructured nature of healthcare data makes it difficult for health systems to integrate it with other high-value data sets, which will cause significant delays and even prevent health system leaders from having an accurate understanding of COVID-19’s impact on patients. A key example is the identification of a cohort of patients who may be a donor or recipient candidate for antibodies. To address data extraction and speed to insight challenges, MetiStream built Ember CR to accelerate the analysis of patient and population data for COVID-19.“We want to do everything possible as a company to support the healthcare community’s fight against COVID-19. The best way we know how is through better data so that organizations can quickly leverage all of their clinical information to treat and manage their patient population in the changing environment,” said Chiny Driscoll, CEO of MetiStream. “We thank CIT for their continued support during these unprecedented times, enabling us to accelerate the development and testing of our new product.”Ember CR, which is built upon MetiStream’s scalable, cloud-based end-to-end Ember NLP and AI platform, automates the extraction and processing of structured and unstructured healthcare data found in free text EHR notes and other healthcare documentation formats such as searchable and non-searchable PDFs. The extraction and processing of both structured and unstructured data sets will enable providers and related healthcare organizations to deliver actionable analysis and insights with evidence-based reports, predictive analytics, and “Next Best Action” considerations for cohorts of COVID-19 patients.“CIT is proud of our many portfolio companies going out of their way to make a difference in the fight against COVID-19. MetiStream is actively collaborating with multiple providers and related healthcare organizations to further address various COVID-19 data and analysis needs using the Ember Clinical Reviewer solution,” said Jennifer O’Daniel, Investment Director at CIT GAP Funds. “Information access and analysis are critical to managing challenges facing the healthcare industry today. We look forward to seeing what MetiStream will do next.”About MetiStream
MetiStream specializes in addressing the challenging unstructured data problem in the healthcare industry. MetiStream’s mission is to help organizations access and gain value from all of their data assets to develop a deeper understanding of the patient population, improve quality and proactively impact patient outcomes. MetiStream’s SaaS-enabled Ember solution is an interactive healthcare analytics product delivering an end-to-end solution at the intersection of NLP and predictive analytics. Located in the Washington DC area, MetiStream is led by industry experts with backgrounds from top technology companies. For more information, please visit www.metistream.com.About CIT GAP Funds
CIT GAP Funds makes seed-stage equity investments in Virginia-based technology, clean tech and life science companies with a high potential for achieving rapid growth and generating significant economic return for entrepreneurs, co-investors and the Commonwealth of Virginia. CIT GAP Funds’ investments are overseen by the CIT GAP Funds Investment Advisory Board (IAB). This independent, third-party panel consists of leading regional entrepreneurs, angel and strategic investors, and venture capital firms such as New Enterprise Associates, Grotech Ventures, Valhalla Partners, Harbert Venture Partners HIG Ventures, Edison Ventures, In-Q-Tel, Intersouth Partners, SJF Ventures, Carilion Health Systems, Johnson & Johnson, General Electric, and Alpha Natural Resources. For more information, please visit www.citgapfunds.org.About the Center for Innovative Technology (CIT)
Investing in Virginia’s Growth | CIT concentrates on the early commercialization and seed funding stages of innovation, helping innovators and tech entrepreneurs launch and grow new companies, create high paying jobs and accelerate economic growth throughout the entire state of Virginia. Founded in 1985, CIT accelerates next generation technologies and technology companies through commercialization, capital formation, market development initiatives, and expansion of broadband throughout Virginia. Our programs include | CIT GAP Funds | Commonwealth Research Commercialization Fund (CRCF) | Virginia Founders Fund | Broadband/Rural Broadband | Smart Communities | Cybersecurity | Unmanned Systems | SBIR/STTR Support (Small Business Innovation Research (SBIR) & Small Business Technology Transfer (STTR) programs) | University Partnerships | Startup Company Mentoring & Engagement. CIT’s CAGE Code is 1UP71. Contact: 2214 Rock Hill Road #600, Herndon, VA 20170 | 703.689.3000 | www.cit.org | You can also follow CIT on Twitter, LinkedIn, and Facebook.Dan Warren
dan@goLaunchTech.com Sara (Pomakoy) Poole
Center for Innovative Technology (CIT)
Second Front Systems Raises $6 Million to Provide Immediate Impact to National Security, led by ARTIS Ventures
San Francisco, CA, July 07, 2020 (GLOBE NEWSWIRE) — Second Front Systems, a software company working to disrupt the traditional aerospace and defense industry by acting as a beachhead for cutting-edge startups, today announced an oversubscribed $6 million in seed funding led by ARTIS Ventures. Additional investors include Kleiner Perkins, 8VC, Gula Tech Adventures, and Abstract Ventures. The venture funding will be used to expand the capabilities of Second Front’s software platform, Atlas Fulcrum, which has recently received a major contract award from the General Services Administration (GSA) and the Air Force’s AFWERX. The U.S. military recognizes that commercially driven tech, such as autonomy, cyber, biotech, and AI, has surpassed the defense base in relevance to national security in the 21st century. Acting as a “digital prime,” the Atlas Fulcrum platform empowers the U.S. government to regain control from the traditional defense industry in scouting, vetting, and securely fielding cutting-edge technology at scale.Austin Walne, partner at ARTIS Ventures will join Second Front’s board with General Peter Pace, former Chairman of the Joint Chiefs of Staff, General Stanley McChrystal, former commander of U.S. and international forces in Afghanistan, and Alberto Yepez, co-founder and managing director of ForgePoint Capital.
“The U.S. Military is actively seeking advances in artificial intelligence and synthetic biology. This aligns with ARTIS Ventures’ focus on the convergence of computer science and life science,” said Austin Walne, partner at ARTIS Ventures, whose firm is also an investor in Palantir. “Second Front’s executive team comes with proven military backgrounds, giving them an insider’s perspective on vetting and integrating technologies that will have an immediate impact on national security.”
Second Front was started by former Marine Corps Major Peter Dixon, a scout sniper platoon commander who worked with In-Q-Tel and DARPA to pioneer counter-cartel and counter-insurgency technologies, including early adoption of Palantir, at the State Department and Pentagon, and retired Marine Corps Colonel Mark Butler, a fighter and test pilot who helped form the Marines’ arm of Cyber Command.
“I came back from combat deployments in Iraq and Afghanistan where my men and I were hamstrung by outdated technology that negated what should have been an advantage against insurgent adversaries,” said Second Front CEO Peter Dixon. “Subsequently, at the Pentagon, I watched as billions of dollars were awarded to traditional defense companies, many of whom were unable to deliver usable technology to front-line troops. This venture financing and initial partnerships gives Second Front the velocity to build a new type of ‘lean systems integrator’ that can harness the innovations of the American entrepreneurial ecosystem where the traditional defense firms have failed.” Biotech and the Military
As the U.S. military looks to reshape the national security and innovation base to respond to pandemics and embrace evolving technologies such as synthetic biology, biotech has become a crucial focus area for the government.
As stated by Dr. Will Roper, Assistant Secretary of the Air Force for Acquisition, Technology and Logistics in Breaking Defense, “There are so many breakthroughs that are happening. We don’t typically think about biology as a core competency in the Air Force, but biology teaches us a ton.”
Second Front Systems is a public benefit corporation operating in a new class of venture-backed defense companies that includes Palantir, Anduril, and Rebellion Defense.
About Second Front Systems
Second Front Systems is a veteran-owned small business that builds software so U.S. and allied governments can harness disruptive technology from venture capital-backed, commercially proven companies. For more information visit https://secondfront.com/.
About ARTIS Ventures
ARTIS Ventures (AV) partners with entrepreneurs who are driven to impact the world by reshaping and reinventing industries. The team supports its portfolio companies through their entire life-cycle, from initial venture investment to public offering and beyond. As an early leader in the emerging TechBio sector, ARTIS Ventures funds companies at the intersection of computer science and life science, applying engineering principles and data-enabled discovery to the healthcare space. Notable companies the firm has backed include YouTube, Modern Meadow, Nimble Storage, StemCentrx, Palantir, IDbyDNA, Versa Networks, Cohesity, Locus Biosciences, Eko, Excision BioTherapeutics, Aether, Unnatural Products, Inc., and more. For more information visit www.av.co or email email@example.com.
DIAGNOS Announces that its Client in California, the Chaparral Medical Group of Clinics, is Reopening the Screening Services for Diabetic Retinopathy after the COVID-19 Shutdown
BROSSARD, Quebec, July 07, 2020 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues using advanced Artificial Intelligence (AI), is pleased to announce that its client, Chaparral Medical Group (“Chaparral”), is reopening amid additional safety extra measures being implemented to address the COVID-19 situation.
Dr. Prasad Jeereddi, MD, Diabetes Specialist, President, and Medical Director of Chaparral stated: “The remote screenings are conducted using a telemedicine application which temporarily replaces the requirement for patients to be seen in person by a specialist. It only takes 5 minutes to perform the screening test. It prevents the need for the diabetic patient to get their eyes tested in a different location. Chaparral operates 33 clinics across the state of California. Diabetic patients are vulnerable to COVID-19 and the convenience of the test in our clinic reduces the risk for COVID-19 exposure.”Telemedicine refers to the practice of caring for patients remotely when the provider and patient are not physically present with each other.Mr. Yves-Stephane Couture, vice-president of sales at DIAGNOS added: “We are pleased to provide extra service at the point of care (POC) for Chaparral’s patients. While the patient is in the clinic, it’s an excellent opportunity to check their eyes for diabetic retinopathy. Diabetes is the most common cause of vision impairment and blindness among working-age adults in the United States as per the US Centers for Disease Control and Prevention.”
About Chaparral Medical Group
Chaparral Medical Group is a multi-specialty healthcare group serving the communities of Claremont, La Verne, San Dimas, Fontana, Pomona, Rancho Cucamonga, Upland, Chino Hills and Diamond Bar in Southern California. Over 20 primary care physicians serve as the group’s clinical core, and work together with their medical and surgical specialists to provide outstanding care to the patient population of Southern California. They have been serving the community since 1978 and their unwavering commitment to patient care and physician work satisfaction are what have driven them to become the most trusted and relied-upon group of physicians in their area.
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet and is compatible with all recognized image formats and brands of fundus cameras and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.Additional information is available at www.diagnos.com and www.sedar.comThis news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.For further information, please contact: Mr. André Larente, President
Tel: 450-678-8882 ext. 224
Fluent.ai Named a Cool Vendor by Gartner
MONTREAL, July 07, 2020 (GLOBE NEWSWIRE) — Fluent.ai, a leading provider of offline, small footprint and multilingual speech understanding solutions for original equipment manufacturers (OEMs) looking to deliver lightweight solutions for consumer devices, announces it has been recognized in the Cool Vendors in Natural Language Technology1 report by Gartner.Fluent.ai’s groundbreaking speech-to-intent technology uses neural networks to directly map a user’s speech to intended action based on acoustic sounds alone, completely bypassing the need for speech-to-text transcription and reliance on a Cloud connection. This acoustic-only approach enables Fluent.ai to create small footprint, low power speech understanding systems that work fully offline on edge devices. Fluent.ai technology also works well in noisy environments and offers industry-leading multilingual capabilities.Fluent’s WakeWord and Automatic Intent Recognition (“Air”) software solutions provide fast-response voice activation and control capabilities that are ideal for consumer devices such as smart home appliances, wearable fitness trackers and wireless headphones. By working fully offline on device, Fluent.ai protects consumer privacy and has the flexibility to be used in any environment. Fluent’s solutions are tailor-made and can be built to support any language, any accent, and even multiple languages and accents in a single small-footprint system.“To us, our recognition in the Cool Vendors in Natural Language Technology report by Gartner is confirmation that Fluent.ai is well on its way to fulfilling our company mission to voice enable the world’s devices,” said Probal Lala, CEO of Fluent.ai. “We aim to provide a voice solution that works for everyone regardless of their language, accent or environment. It’s this focus along with our small footprint and low power requirements that we believe will make our OEM customers successful in offering voice control capabilities to their end users. In this era of COVID-19, we anticipate these capabilities will only grow in importance as touchless user interfaces become more and more of a necessity.”1 Gartner, “Cool Vendors in Natural Language Technology,” Bern Elliot, Anthony Mullen, Afraz Jaffri, Jessica Ekholm, Tracy Tsai, 16 April 2020.
Latest News1 year ago
Bleckwen Raises $10m and Appoints David Christie as CEO
Artificial Intelligence1 year ago
Kneron Debuts Edge AI Chip, Bringing AI to Devices Everywhere
Artificial Intelligence1 year ago
Chartis Research Names FICO a Category Leader in AI for Financial Services
Artificial Intelligence1 year ago
CredoLab extends smartphone-based scoring to insurers
Artificial Intelligence1 year ago
LogRhythm Scores the Singapore Business Review Technology Excellence Award 2019 for Cyber Security – Computer Software
Artificial Intelligence1 year ago
Tuya Exhibiting Products from its Global Clients that are “Powered by Tuya”
Artificial Intelligence1 year ago
Chengdu Tianfu Software Park Reflects the Vitality of IP Innovation
Artificial Intelligence3 months ago
Special Report: Coronavirus and the Housing Industry